

Amendments to the Claims

Claim 1 (currently amended): A molecular adjuvant for enhancing an immune response to an immunogen comprising:

~~a C5a response selective agonist having binding affinity~~
~~for~~ targeting ligand which binds specifically to a C5a
receptor of an antigen presenting cell, said ~~selective agonist~~
targeting ligand being covalently linked to said immunogen,
whereby binding of said molecular adjuvant to said antigen
presenting cell C5a receptor activates said antigen presenting
cell, effecting delivery of said immunogen to an antigen
presenting pathway of said antigen presenting cell, wherein
said targeting ligand is selected from the group consisting of
C5a, a peptide agonist analog of C5a comprising the C-terminal
ten residues of C5a, and a C-terminal C5a agonist analog.

Claim 2 (cancelled)

Claim 3 (cancelled)

Claim 4 (currently amended): A molecular adjuvant as claimed
in claim 1, wherein said ~~selective agonist~~ targeting ligand is
selected from the group consisting of C5a and a peptide
agonist analog of C5a comprising the C-terminal ten residues
of C5a.

Claim 5 (currently amended): A molecular adjuvant as claimed
in claim 4, wherein said ~~selective agonist~~ targeting ligand is
a peptide comprising the ~~sequence YSFKPMPLaR, which is~~
~~Sequence I.D. No.~~ SEQ ID NO: 1.

Claim 6 (currently amended): A molecular adjuvant as claimed
in claim 1, comprising a ~~selective agonist~~ targeting ligand

and an immunogen having the sequence ~~YKQGGFLGLYSFKPMPLaR,~~
~~which is Sequence I.D. No. of SEQ ID NO: 2.~~

Claim 7 (currently amended): A molecular adjuvant as claimed in claim 1, wherein said ~~selective-agonist~~ targeting ligand and said immunogen are linked by a spacer moiety.

Claim 8 (cancelled)

Claim 9 (cancelled)

Claim 10 (original): A molecular adjuvant as claimed in claim 1, wherein said immunogen comprises at least one substance selected from the group consisting of peptides, glycopeptides, phosphopeptides, lipopeptides, proteins, glycoproteins, phosphoproteins, lipoproteins, carbohydrates, nucleic acids and lipids.

Claim 11 (original): A molecular adjuvant as claimed in claim 10, wherein said immunogen comprises a peptide.

Claim 12 (original): A molecular adjuvant as claimed in claim 10, wherein said peptide comprises an epitope of human mucin-1.

Claim 13 (original): A molecular adjuvant as claimed in claim 10, wherein said immunogen comprises a protein.

Claim 14 (original): A molecular adjuvant as claimed in claim 13, wherein said protein comprises serum amyloid A (SAA).

Claim 15 (original): A molecular adjuvant as claimed in claim 14 having the formula SAA-K-Ahx-YSFKPMPLaR, which is SAA-conjugated SEQ ID NO: 8.

Claim 16 (original): A molecular adjuvant as claimed in claim 1, wherein said immunogen comprises a tumor-specific antigen.

Claim 17 (original): A composition for enhancing an immune response to an immunogen in a subject in which said enhanced immune response is desired, said composition comprising the molecular adjuvant of claim 1 in a biologically compatible medium.

Claims 18-25 (cancelled)

Claim 26 (currently amended): The A method for enhancing an immune response to an immunogen in a subject in which said enhanced immune response is desired, comprising administration of an effective amount of the composition of claim 17 wherein the immunogen is an antigenic substance selected from the group consisting of peptides, proteins, glycopeptides, glycoproteins, phosphopeptides, phosphoproteins, lipopeptides, lipoproteins, carbohydrates, nucleic acids, and lipids.